Infectious Diseases Therapeutics Market Research Reports

"...... Cefprozil market is projected to grow from US$ 140 million in 2023 to US$ 170.1 million by 2029, at a Compound Annual Growth Rate (CAGR) of 3.3% during the forecast period. Global Cefprozil key players include Orchid, Taj Pharma, Dhanuka, Qil......"

"...... llin market is projected to grow from US$ 4783.5 million in 2023 to US$ 5812.3 million by 2029, at a Compound Annual Growth Rate (CAGR) of 3.3% during the forecast period. Global Amoxicillin main players include GSK, Novartis, Centrient Pharma......"

"...... 1 million in 2023 to US$ 1346.9 million by 2029, at a Compound Annual Growth Rate (CAGR) of -0.3% during the forecast period. Market competition is intense. Qilu Antibiotics, Nectar Lifesciences, Shandong Ruiying Pioneer Pharmaceutical, NCPC a......"

"...... e called as Fragyl Orvagil, Trichazol, Metronid, etc. The global Metronidazole market is projected to grow from US$ 112.4 million in 2023 to US$ 109.1 million by 2029, at a Compound Annual Growth Rate (CAGR) of -0.5% during the forecast period......"

"...... weight is 344.8 g/mol.Clotrimazole is an inhibitor of ergosterol biosynthesis. It has many ecotoxicological properties in common with a range of fungicides used in agriculture. Clotrimazole is a broad-spectrum antimycotic agent effective pathogenic ......"

"...... h a CAGR of 3.65% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Metronidazole market, with a systematical description of the status quo......"

"...... leum Industries, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global market for Polymixin from 2017-2022, and provides extensive......"

"...... region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global market for Clotrimazole from 2017-2022, and provides extensive market forecasts from 2023......"

"...... .58% during the forecast years. Cefprozil is a second-generation cephalosporin antibiotic that can be used to treat bronchitis or other bacterial infections. The cefprozil may be in the form of a tablet or a suspension. T......"

"...... recast period. Cephalexin is mainly infected with Gram-positive and negative bacteria, influenza, such as hemorrhagic sepsis, streptococcosis, and is used to treat various inflammatory diseases such as infectious pleuropneumonia and pneumonia......."